Following on from several recalls of pharmaceutical products, the issue of nitrosamines in drugs has become a high priority. The European Medicines Agency is now requiring risk assessments of nitrosamine exposure risk to be completed by the 26th of March. This webcast will look at nitrosamines, where they may be formed in a pharmaceutical environment, and how the dedicated nitrosamine detectors can be used in both screening and more detailed analysis.
Key Learning Objectives:
Who Should Attend:
For questions please contact Martha Devia: email@example.com_1593902006593